Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1695 • ACR Convergence 2025
The B Cell Compartment Exhibits a Pro-Inflammatory Skewing During Progression to Rheumatoid Arthritis
Ziyuan He¹, Marla Glass¹, Mark Gillespie¹, Elisabeth Dornisch¹, Pravina Venkatesan², Troy Torgerson³, Kevin Deane⁴, Gary Firestein⁵, Adam Savage¹, Xiaojun Li¹, V. Michael Holers⁶, Fan Zhang⁷, David Boyle⁸, Christy Bennett¹, Kristine Kuhn⁹, Kristen Demoruelle¹⁰, Peter Skene¹¹ and Ananda Goldrath¹¹, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Insitute, Seattle, WA, ³Allen Institute for Immunology, Enumclaw, WA, ⁴University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁵University of California, San Diego, San Diego, CA, ⁶University of Colorado, Denver, CO, ⁷The University of Colorado, Aurora, CO, ⁸UCSD, La Jolla, CA, ⁹²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO, ¹⁰University of Colorado Anschutz Medical Campus, Golden, CO, ¹¹Allen Institute for Immunology, Seattle
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and bone destruction. RA is preceded by a subclinical phase defined by elevated…
Abstract Number: 1644 • ACR Convergence 2025
Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis
Misti Paudel¹, Leah Santacroce², Nancy Shadick³, Michael Weinblatt⁴ and Daniel Solomon⁵, ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham & Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Prior studies have observed that patient-reported outcomes, such as pain, are risk factors for progression to difficult-to-treat RA (D2T-RA), a state of multi-treatment failure.…
Abstract Number: 1360 • ACR Convergence 2025
Evaluating Causal Effects of Biologic and Targeted Synthetic Disease-modifying Anti-rheumatic Drugs Targets in Rheumatoid Arthritis Using Mendelian Randomisation
Mihye Kwon¹, Chung-il Joung¹ and Young Soo Song², ¹Konyang University Hospital, Daejeon, Republic of Korea, ²Konyang University Hospital, Daejeon, Taejon-jikhalsi, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease in which biologic and targeted synthetic DMARDs (bDMARDs, tsDMARDs) have substantially improved clinical outcomes. While randomized…
Abstract Number: 1343 • ACR Convergence 2025
Six-Minute Walk Distance as a Functional Measure in Rheumatoid Arthritis-associated Interstitial Lung Disease Reflecting Both Lung and Joint Involvement
Sung Hae Chang¹, You-Jung Ha², Sung Won Lee³, Misti Paudel⁴, Gregory McDermott⁵, Qianru Zhang⁶, Min Uk Kim⁷, Jeong Seok Lee⁸, Chan Ho Park⁹, Ji-Won Kim¹⁰, Jang Woo Ha¹¹, SANGWAN CHUNG¹², Eun Ha Kang¹³, Yeon-Ah Lee¹², Yong-Beom Park¹⁴, Jung-Yoon Choe¹⁵, Eun Young Lee¹⁶ and Jeffrey Sparks¹⁷, ¹Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ²Seoul National University Bundang Hospital, Seongnam, South Korea, ³Soon Chun Hyang University Hospital, Seoul, South Korea, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Harvard Medical School, Boston, MA, ⁷SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁸Korea Advanced Institute of Science and Technology, KAIST, DaeJeon, Republic of Korea, ⁹Soonchunhyang University College of Medicine, Cheonan, Republic of Korea, ¹⁰Daegu Catholic University School of Medicine, Nam-gu, Daegu, Republic of Korea, ¹¹Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea, ¹²Kyung Hee University Medical Center, seoul, Republic of Korea, ¹³Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ¹⁴Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ¹⁵Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Republic of Korea, ¹⁶Seoul National University College of Medicine, Seoul, South Korea, ¹⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: The six-minute walk distance (6MWD) measures functional capacity in cardiopulmonary diseases, predicts mortality in interstitial lung disease (ILD), and is used as an endpoint…
Abstract Number: 1326 • ACR Convergence 2025
Association Between Physical Function and Nutritional Status in Rheumatoid Arthritis Patients
Yasumori Sobue¹, Mochihito Suzuki², Yoshifumi Ohashi³, Shuji Asai² and Shiro Imagama², ¹Sobue Orthopedic Clinic Yatomi, Aichi, Japan, ²Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Aichi Medical University, Graduate School of Medicine, Aichi, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that primarily affects the joints but also has substantial implications for physical function. Persistent inflammation may…
Abstract Number: 1311 • ACR Convergence 2025
Decade-Based Trends in First Remission Among Rheumatoid Arthritis Patients: A Population-Based Study
Georges El Hasbani¹, Roslin George², Anne Shurtz¹, Cynthia Crowson³ and Elena myasoedova², ¹Mayo Clinic, Rochester, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Early and aggressive treatment of rheumatoid arthritis (RA) has been linked to improved remission rates, but achieving early and sustained remission remains a challenging…
Abstract Number: 1189 • ACR Convergence 2025
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
Valerie Devauchelle¹, Swati Ghanshani², CAROLE SIPS³, Rainer Hillenbrand³, Carol Lau⁴, Wolfgang Hueber⁵, Claire Bonal³ and Stephen Oliver⁶, ¹UBO, Brest, France, ²Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ³Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via dual mechanism: depletion of B…
Abstract Number: 1039 • ACR Convergence 2025
CAR-T Therapy in Rheumatoid Arthritis: A Health Systems Analysis of Cost and Global Equity
Asrith Reddy Gandu¹ and Kolluri Prathyusha², ¹Davao medical school foundation, Hyderabad, India, ²University of delaware, Newark, DE
Background/Purpose: Refractory rheumatoid arthritis (RA) affects 30–40% of patients with limited therapeutic options and high disability burdens. Although CAR‑T therapy has been transformative in oncology…
Abstract Number: 0980 • ACR Convergence 2025
Expansion of Viral-Reactive CD8+ T cell Repertoire Stratified by Pathotype in New-onset ACPA+ Rheumatoid Arthritis
Carl Coyle¹, Wittaya Suwakulsiri², Lukas Andriessen³, Megan Soon⁴, Pascale Wehr⁵, Sumera Qureshi⁶, Christopher Altmann⁷, Annabelle Small⁸, Vincent Wong⁹, Andrew Cope⁶, Kevin Wei¹⁰, Hendrik Nel⁵, Mihir Wechalekar¹¹ and Ranjeny Thomas², ¹Kings College London, London, United Kingdom, ²Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ³Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia, ⁴Frazer Institute, The University of Queensland, Brisbane, Australia, ⁵University of Queensland, Woolloongabba, Queensland, Australia, ⁶King's College London, London, United Kingdom, ⁷Flinders University, Adelaide, Australia, ⁸Flinders University, Bedford Park, South Australia, Australia, ⁹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ¹⁰Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹¹Flinders Medical Centre, Adelaide, Australia
Background/Purpose: Development of Rheumatoid Arthritis (RA) is strongly associated with specific HLA-DRB1 genotypes and the HLA-DR antigen binding groove, the shared epitope. HLA-B*08 also increases…
Abstract Number: 0871 • ACR Convergence 2025
The gut microbiome shapes MTX pharmacology and is linked to treatment outcomes
Vanya Sofia Villa Soto¹, Diego Orellana², Erin Reilly³, Chloe Heath², Alexandra Degraeve², Mohana Mukherjee², darren Dumlao², Rebecca Blank⁴, steven Yu², Noah Perlmutter², Judith Ashouri², Jose Scher⁵, andrew Patterson³, Peter Turnbaugh² and Renuka Nayak⁶, ¹University of California, San Francisco, San Francics, CA, ²University of California, San Francisco, San Francisco, CA, ³Pennsylvania State University, University Park, PA, ⁴NYU Langone Health, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Despite advances in targeted therapeutics, methotrexate (MTX) remains the first-line therapy in the treatment of rheumatoid arthritis (RA) and other inflammatory arthritides. However, more…
Abstract Number: 0799 • ACR Convergence 2025
Citrullination of neutrophil serine proteases enhances proteolytic activity, stability and autoantigenicity in Rheumatoid Arthritis
Mario Navarrete Lagos, Ramiza Zaman, Jun Kim, Jeba Atkia Maisha, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: In Rheumatoid Arthritis (RA), autoantibodies develop against endogenous proteins containing the amino acid citrulline, which results from a post-translational modification of arginine catalyzed by…
Abstract Number: 0497 • ACR Convergence 2025
Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)
Nariaki Hao and Naoki Kondo, Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital, Niigata, Japan
Background/Purpose: To retrospectively evaluate drug survival and reasons for discontinuation of eight biological disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients using the Niigata…
Abstract Number: 0480 • ACR Convergence 2025
Efficacy and safety of tacrolimus and its serum concentration in patients with rheumatoid arthritis with inadequate response to methotrexate
Chan-Bum Choi, Hanyang University Hosptial for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Addition of a biologic disease-modifying antirheumatic drug (bDMARD) or targeted synthetic DMARD (tsDMARD) is recommended in patients with rheumatoid arthritis (RA) with inadequate response…
Abstract Number: 0463 • ACR Convergence 2025
Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis
Solana Cushing¹, Susan Goodman², Michael Parides¹, Hadeel Abdul-Rehman¹, Daniel Ramirez², Edward DiCarlo², Kristine Carandang³, Renee Davis⁴, Rebecca Blank⁵, Laura Donlin¹, Anna Helena Jonsson⁶, Amit Lakhanpal², Bella Mehta⁷, Dana Orange⁸ and Melanie smith², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ⁴New York, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶University of Colorado School of Medicine, Aurora, CO, ⁷Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, ⁸The Rockefeller University, New York, NY
Background/Purpose: Synovial tissue pathotype may indicate treatment response in RA, but synovial biopsies are not widely available. Synovial fluid (SF) is a promising surrogate. We…
Abstract Number: 0447 • ACR Convergence 2025
Foot-pressure distribution method for detection of foot joint arthritis in patients with rheumatic diseases
Hayagrivas Manicka Bharathkumar¹, Emani Srinija Reddy¹, Bhaskar Pandey², Suryansh Saini¹, Sangeet Rathi¹, Saransh Verma¹, Chinmay Prakash Swami², Deepak Joshi² and Ranjan Gupta¹, ¹All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi, Delhi, India, ²Indian Institute of Technology (IIT), Delhi, Delhi, Delhi, India
Background/Purpose: Rheumatoid arthritis (RA) and Seronegative Spondyloarthritis (SSA), the most common types of inflammatory arthritis, have significant ankle and foot joint involvement. However, these joints…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].